114 related articles for article (PubMed ID: 12512147)
1. [Hormonal chemotherapy for hormone-refractory prostate cancer].
Nishimura K; Nakai Y; Shimizu K; Tokizane T; Arai Y; Inoue H; Takaha N; Nonomura N; Okuyama A; Kamoi K; Ukimura O; Miki T; Koide T; Ichikawa Y; Nishimura K; Sugao H; Yamaguchi S; Takatera H; Uchida K; Miura H
Hinyokika Kiyo; 2002 Nov; 48(11):713-8. PubMed ID: 12512147
[TBL] [Abstract][Full Text] [Related]
2. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
[TBL] [Abstract][Full Text] [Related]
3. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
[TBL] [Abstract][Full Text] [Related]
4. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
Hatano K; Nonomura N; Nishimura K; Kawashima A; Mukai M; Nagahara A; Nakai Y; Nakayama M; Takayama H; Tsujimura A; Okuyama A
Jpn J Clin Oncol; 2011 Feb; 41(2):253-9. PubMed ID: 21071389
[TBL] [Abstract][Full Text] [Related]
8. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
9. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
[TBL] [Abstract][Full Text] [Related]
10. [Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients].
Kawaguchi T; Mayama I; Iwabuchi I; Ogasawara M; Tsukui A
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1921-5. PubMed ID: 20948257
[TBL] [Abstract][Full Text] [Related]
11. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Morinaga A; Sukehiro A; Suetsugu N; Katagiri K; Yamada A; Noda S
Prostate; 2004 Jun; 60(1):32-45. PubMed ID: 15129427
[TBL] [Abstract][Full Text] [Related]
12. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
[TBL] [Abstract][Full Text] [Related]
13. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
Koutsilieris M; Mitsiades CS; Bogdanos J; Dimopoulos T; Karamanolakis D; Milathianakis C; Tsintavis A
Clin Cancer Res; 2004 Jul; 10(13):4398-405. PubMed ID: 15240528
[TBL] [Abstract][Full Text] [Related]
14. Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
Odrazka K; Vaculikova M; Dolezel M; Petera J; Moravek P; Prosvic P; Zoul Z; Vosmik M; Dolezal J; Simakova E
Oncol Rep; 2005 Oct; 14(4):1077-81. PubMed ID: 16142375
[TBL] [Abstract][Full Text] [Related]
15. Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.
Serretta V; Altieri V; Morgia G; Siragusa A; De Grande G; Napoli M; Falsaperla M; Melloni D; Allegro R
Urol Int; 2009; 83(4):452-7. PubMed ID: 19996654
[TBL] [Abstract][Full Text] [Related]
16. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
17. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
18. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.
Glode LM; Barqawi A; Crighton F; Crawford ED; Kerbel R
Cancer; 2003 Oct; 98(8):1643-8. PubMed ID: 14534880
[TBL] [Abstract][Full Text] [Related]
19. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma.
Daliani DD; Assikis V; Tu SM; Papandreou CN; Pagliaro LC; Holtkamp T; Wang X; Thall PF; Logothetis CJ
Cancer; 2003 Feb; 97(3):561-7. PubMed ID: 12548597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
